Clinical Trials · NCT05872620
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 1,613
- Start date
- Jun 2023
- Locations
- 136 sites, 11 countries
- Primary endpoint
- Mean Percent Change from Baseline in Body Weight